INTRODUCTION
Innate immunity is considered to be essential for host defense against invading microbial pathogens and is promptly activated after recognition of pathogen associated-molecular patterns (PAMPs) (1, 2) . Pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) play an important role in this innate immune reaction. TLRs recognize various PAMPs and trigger the release of inflammatory cytokines and type I interferons (IFNs) for host defense.
Broadly, activation of TLRs by their respective ligands leads to the recruitment of one or more Toll/IL-1 Receptor (TIR) domain-containing adapter molecules, such as myeloid differentiation protein-88 (MyD88) or toll-interleukin-1 receptor domain-containing adapter inducing interferon-β (TRIF) (3) . The activation of TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR11 with their ligands recruits MyD88. However, the activation of TLR3 with its ligand recruits TRIF, as does activation of TLR4. This recruitment of adaptor molecules triggers signaling pathway cascades and the activation of transcription factors such as nuclear factor-κB (NF-κB) and IFN regulatory factor 3 (IRF3), leading to the induction of inflammatory cytokines, chemokines, and type I IFNs (3) .
Upon stimulation, MyD88 recruits IL-1 receptor-associated kinase (IRAK), IRAK-4, and IRAK-1. IRAK-1 associates with tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), leading to the activation of NF-κB through the canonical I kappa B kinase (IKK) complex. This signaling pathway induces the expression of pro-inflammatory genes products, including cytokines and cyclooxygenase-2 (COX-2) (4).
In addition to proinflammatory signals, TLR3 and TLR4 initiate the TRIF-dependent signaling pathway to induce inflammatory cytokines and type I IFNs (4) . TRIF induces the activation of IRF3 as well as the expression of IFN-inducible genes such as IFN-β, interferon inducible protein-10 (IP-10), and regulated on activation normal T-cell expressed and secreted (RANTES) through the activation of IKK-related kinases, inducible IKK (IKKi)/IKKε, and TRAF family members associated with NF-κB activator-binding kinase1 (TBK1) (5-7). The TRIF-dependent pathway also induces MyD88-independent NF-κB activation through the association of the C-terminal domain of TRIF with receptor-interacting protein-1 (RIP1) (3) .
Fumaric acids are α,β-unsaturated electrophilic compounds, with pyrrolidinone a heterocyclic organic compound containing nitrogen in a five-membered ring. Previously, we synthesized a fumaryl pyrrolidinone, (E)-isopropyl 4-oxo-4-(2-oxopyrrolidin-1-yl)-2-butenoate (IPOP) (Fig. 1A) , which contains a fumaric acid isopropyl ester and pyrrolidinone (8) . Further, we http://bmbreports.org BMB reports reported that IPOP suppresses TLR agonist-induced NF-κB activation and cyclooxygenase-2 expression (8). However, both the fumaric acid isopropyl ester and pyrrolidinone do not inhibit lipopolysaccharide (LPS)-induced NF-κB activation (8) . These results suggest that the fumaryl pyrrolidinone derivative IPOP may play a role in the inhibition of TLR activation, which preludes development of many chronic inflammatory diseases.
Previously, we reported that IPOP inhibits the MyD88-dependent signaling pathway of TLRs (8) . IPOP inhibits NF-κB activation, COX-2 expression, and IκBα degradation induced by TLR2 and TLR4 agonists. IPOP also suppresses NF-κB activation induced by MyD88-dependent downstream molecules. However, whether or not IPOP inhibits the TRIF-dependent signaling pathway of TLRs remains unknown. Therefore, the present study attempted to identify the anti-inflammatory target of IPOP in the TRIF-dependent signaling pathway of TLRs.
RESULTS AND DISCUSSION

IPOP suppresses LPS-induced NF-κB and IRF3 activation
To determine whether or not IPOP could modulate TLR-mediated signaling pathways, NF-κB activation induced by LPS was used as a readout of TLR activation. IPOP suppressed the LPS (TLR4 agonist)-induced activation of NF-κB in a dose-dependent manner, as determined by luciferase reporter gene assay (Fig. 1B) . The next experiment determined whether or not IPOP could inhibit the TRIF-dependent signaling pathway of TLR4. Since this pathway induces the activation of IRF3 transcription factor (7), IRF3 activation was used as a readout for the TRIF-dependent pathway. IPOP inhibited LPS-induced IRF3 activation, as determined by reporter gene assay using the IFNβ promoter domain containing the IRF3 binding site (IFNβ PRDIII-I) (Fig. 1C) . IPOP also inhibited the phosphorylation of IRF3 as determined by Western blotting (Fig. 1D) . These results supported the suggestion that IPOP inhibits the TRIF-dependent signaling pathway derived from TLR4 activation.
IPOP suppresses poly[I:C]-induced NF-κB and IRF3 activation
Although the TLR4 signaling pathway can trigger the activation of IRF3 mediated through both the MyD88-and TRIF-dependent pathways, the TLR3 signaling pathway triggers the activation of IRF3 only through the TRIF-dependent pathway. Therefore, induction of IRF3 activation by poly[I:C] can be http://bmbreports.org used as a readout for the TRIF-dependent pathway. IPOP inhibited poly[I:C]-induced NF-κB and IRF3 activation, as determined by luciferase reporter gene assay ( Fig. 2A and 2B ).
IPOP suppresses LPS or poly[I:C]-induced IP-10 expression
To further determine whether or not IPOP could modulate the TRIF-dependent pathway, the expression of genes associated with the TRIF-dependent pathways, such as IP-10, was measured by luciferase reporter gene assay and enzyme-linked immunosorbent assay. IPOP inhibited LPS or poly[I:C]-induced IP-10 expression (Fig. 3A-D) . Further, IPOP suppressed the activation of transcription factors and the expression of target genes induced by TLR3 or TLR4 agonist.
IPOP does not inhibit activation of IRF3 induced by downstream signaling components of the TRIF-dependent pathway of Toll-like receptors
Presently, to further identify the molecular targets of IPOP for the inhibition of the TRIF-dependent pathway, the downstream component (TRIF) of the pathway was transfected into 293T cells. The TRIF-dependent pathway of TLRs led to IRF3 activation mediated through TRIF and TBK1. IPOP did not inhibit TRIF-induced IRF3 activation, as determined by IRF3 binding site (IFNβ PRDIII-I) reporter gene assay (Fig. 4A) . Further, MBP chemiluminescence detection assay determined that IPOP did not suppress TBK1 kinase activity (Fig. 4B) . Collectively, the results support the suggestion that the inhibition targets of IPOP are the upstream components of adaptor molecules, including TLRs or TLR complexes. In a future study, the exact molecular targets of IPOP in the TLR signaling pathways will be identified.
Dysregulated TLR-mediated cellular responses can lead to chronic inflammation, which in turn contribute to the development and progress of many inflammatory diseases. Several studies have reported that pyrrolidinone derivatives have anti-inflammatory activities (9-11). Rolipram, a type 4 phosphodiesterase inhibitor, and N2733, a pyridyl acryloyl pyrrolidinone, inhibits LPS-induced NF-κB activation (9) (10) (11) . Previously, we also demonstrated that the fumaryl pyrrolidinone derivate, IPOP, inhibits TLR2 and TLR4 agonist-induced NF-κB activation and COX-2 expression (8). Collectively, these results support the suggestion that pyrrolidinone derivatives exert their anti-inflammatory activity by regulating TLR signaling pathways.
The MyD88-and TRIF-dependent signaling pathways activate the transcription factor NF-κB and IRFs. Both the NF-κB and IRF families are simultaneously activated in response to microbial infection, but the target genes induced by NF-κB and IRF activation are different. The activation of NF-κB induces proinflammatory cytokines, whereas the activation of IRF3 induces type I IFN genes (12) (13) (14) . Accumulating evidence suggests the importance of the TRIF-dependent signaling pathway of TLRs in inflammatory responses. Expression of the majority (＞70%) of LPS-induced genes is regulated through the TRIF-dependent signaling pathway, suggesting that TRIF-signaling is vital to the TLR4-mediated immune response. These facts suggest that suppression of the TRIF-dependent signaling pathway and the consequent down-regulation of IRF3 activation by IPOP can significantly suppress the target gene expression of TLR signaling pathways.
All these present results raise the important possibility that TLR-mediated inflammatory responses and the resulting risk of many chronic inflammatory diseases can be regulated by the fumaryl pyrrolidinone derivate, IPOP.
MATERIALS AND METHODS
Chemical synthesis
IPOP was synthesized by following an established procedure with modifications (15, 16) . Pivaloyl chloride (1.21 g, 10 mmol) was added to a solution of monoisopropyl fumarate (1.58 g, 10 mmol) and triethylamine (2.02 g, 20 mmol) in 50 ml of tetrahydrofuran at −10 o C. The resulting brown solution was stirred for 1 h, after which LiCl (0.38 g, 9.2 mmol) and 2-pyrrolidinone (0.70 g, 8.3 mmol) were added. The reaction mixture was warmed to room temperature and stirred for 5 h. Twenty milliliters of 1 M HCl was added to the reaction mixture, and the resulting solution was stirred for 1 h. After solvent removal and extractive work-up (aqueous ethyl acetate-saturated NaHCO3), organic layers were dried over MgSO4, filtered, and concentrated. Purification by flash chromatography (ethyl acetate：hexane, 1：2) yielded 1.30 g (70%) of the desired product as a yellow oil. 
Transfection and luciferase assay
The assays were performed as described previously (17, 18) . Briefly, RAW264.7 cells were co-transfected with a luciferase plasmid and HSP70-β-gal plasmid as an internal control using SuperFect transfection reagent (Qiagen) according to the manufacturer's instructions. Luciferase and β-gal enzyme activities were determined using commercial luciferase assay and β-gal enzyme systems (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luciferase activity was normalized by β-gal activity.
Western blotting
The procedure was performed as previously described (19, 20) . Equal amounts of extracts were resolved by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the separated proteins were electrotransferred to a polyvinylidene difluoride membrane. The membrane was then blocked with phosphate-buffered saline containing 0.1% Tween 20 and 3% non-fat dry milk, followed by blotting with the indicated antibodies and secondary antibodies conjugated to horseradish peroxidase (Amersham, Arlington Heights, IL, USA). The reactive bands were visualized with an enhanced chemiluminescence system (Intron, Seongnam, Korea). To reprobe with different antibodies, the membrane was stripped in 0.2 N NaOH at room temperature for 10 min.
In vitro TBK1 kinase assay TBK1 kinase activity was conducted with recombinant human TBK1 (Upstate Biotechnology, Lake Placid, NY, USA) and a chemiluminescence detection myelin basic protein (MBP) assay kit (Upstate Biotechnology) according to the manufacturer's instructions. The assay is designed to measure the phosphotransferase activity of numerous kinases, including TBK1, c-Jun kinase, and mitogen-activated protein kinase, based on the phosphorylation of MBP using a non-radioactive magnesium/ATP cocktail as a phosphate donor. The mixture of reagents, magnesium/ATP, and recombinant TBK1 was added to MBP-coated wells. After incubation of the wells for 60 min at 30 o C, the wells were blocked with blocking buffer. Horseradish peroxidase-conjugated anti-phospho-MBP was added to the wells. After washing with washing buffer, luminescent intensity was determined with the LumiGLO TM chemiluminescent system (Upstate Biotechnology).
Data analysis
Data were obtained from triplicate experiments. Values are expressed as mean ± standard error of the mean (SEM).
